
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is a company with a strong 15+ year track record in developing and commercializing medical devices and solutions for patients with musculoskeletal disorders. With its recent acquisitions and offerings in the spine and interventional pain markets, the company is well-positioned for continued growth and expansion. Its strong execution, potential for high FCF and balance sheet optionality, and potential for multiple sources of upside make it an attractive investment opportunity with a positive outlook.
Bears say
Globus Medical is facing several risks, including a slowdown in spine market growth, potential revenue dis-synergies and disruption following recent mergers, lower sales in its Enabling Technologies segment, and the possibility of lower margins. These risks could negatively impact revenue growth and profitability, leading to a bear case scenario with revenue growth in the low-single digits and stagnant margins. This supports a price target of $84 per share, based on a P/E multiple of 18x the company's estimated 2027 adjusted EPS. This price target is in line with the company's peer group and average 4-year valuation, but significantly lower than the average for profitable MedTech companies with strong growth and high margin profiles, which typically trade at over 20x P/E.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares